PHGE News and Press, Chardan Healthcare Acquisition Corp. From 12/08/25

Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in BX011, its phage program for Staphylococcus aureus ( S. aureus) infections associated with...

The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial An independent Data Monitoring Committee (DMC) completed a safet...

2025-11-14 16:37:11 ET More on BiomX BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript BiomX outlines imminent FDA feedback and targets BX004 Phase IIb data in Q1 2026 while advancing BX011 for diabetic foot infections Seeking Alpha’s Quant Rating on BiomX ...

NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it intends to...

2025-11-12 10:32:20 ET More on BiomX BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on BiomX Historical earnings data for BiomX Financial information for BiomX Read the full article on Seeking Alpha For ...

2025-11-12 10:31:39 ET BiomX Inc. (PHGE) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Marina Wolfson - CFO & Secretary Jonathan Solomon - CEO & Director Conference Call Participants Joseph Pantginis - H.C. Wainwright ...

2025-11-12 09:14:18 ET More on BiomX Seeking Alpha’s Quant Rating on BiomX Historical earnings data for BiomX Financial information for BiomX Read the full article on Seeking Alpha For further details see: BiomX GAAP EPS of $0.29

Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company’s prior Phase 2 success BiomX expects FDA feedback on BX004 clinical hold imminently; Enrollment and dosing of patients outside the U.S. are continui...

NESS ZIONA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will rep...

NESS ZIONA, Israel, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has receiv...